Brazilian study investigates why some HIV patients fail key drug combo
NCT ID NCT04453436
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tracks 2,500 people with HIV in Brazil who are taking a common first-line treatment (tenofovir/lamivudine and dolutegravir) to see why some develop drug resistance. Researchers will test blood samples from those whose viral load remains detectable to look for resistance mutations. The goal is to gather real-world data to improve HIV care in similar settings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could help doctors understand why some people develop drug resistance to common HIV medications, potentially improving future treatment guidelines.
What could go wrong
This is an observational study, not a treatment trial. It only looks at people who have already failed therapy, so it cannot predict who will fail or test new treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Laboratório de Retrovirologia, EP2
São Paulo, São Paulo, 04039-032, Brazil